Trial0

Clinical trial · NCT02000089 · RECRUITING · PHASE3

The Cancer of the Pancreas Screening-5 CAPS5)Study

Sponsor: Johns Hopkins University

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Interventions

  • Secretin · DRUG

    inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.

  • MRI · DIAGNOSTIC_TEST

    MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.

  • Tumor marker gene test with CA19-9 · OTHER

    A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Hereditary Pancreatitis or
* Peutz-Jeghers Syndrome or
* Strong family history of pancreas cancer on one side of the family tree or
* Confirmed germline mutation carrier (BRCA2, FAMMM (CDKN2A/p16), PALB2, BRCA1, ATM, HNPCC, Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM) PRSS1, PRSS2, R122H, N291l, SPINK1, CFTR
* Endoscopic evaluation of pancreas scheduled

Exclusion Criteria:

* Medical comorbidities or coagulopathy that contraindicate endoscopy
* Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis
* Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope
* Poor performance status
* Inability to provide informed consent
* Pregnancy.

Sites (9)

  • Yale University, New Haven, Connecticut · RECRUITING
  • Johns Hopkins Hospital, Baltimore, Maryland · RECRUITING
  • Dana Farber Cancer Center, Harvard University, Boston, Massachusetts · RECRUITING
  • University of Michigan, Ann Arbor, Michigan · RECRUITING
  • NYU Langone Medical Center, New York, New York · RECRUITING
  • Columbia University Medical Center, New York, New York · RECRUITING
  • Case Comprehensive Cancer Center, Case Western Medical Reserve, Cleveland, Ohio · RECRUITING
  • University of Pennsylvania, Philadelphia, Pennsylvania · RECRUITING
  • University of Pittsburgh, Pittsburgh, Pennsylvania · RECRUITING

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2025-10-09.